Champions Oncology (CSBR) Stock Price, News & Analysis

Company Overview

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Key Stats

• Today's Range: $9.00 to $9.72
• 50-Day Range: $9.11 to $10.96
• 52-Week Range: $3.60 to $11.99
• Volume: 32,633 shs
• Average Volume: 20,595 shs
• Market Capitalization: $91.91 million
• P/E Ratio: 33.25
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

Champions Oncology Stock Analysis - MarketRank™

Champions Oncology scored higher than 78% of companies evaluated by MarketBeat, and ranked 234th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Champions Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Champions Oncology has a consensus price target of $12.00, representing about 80.5% upside from its current price of $6.65.

Amount of Analyst Coverage

Champions Oncology has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Champions Oncology is 33.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 233.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Champions Oncology is 33.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.32.

Price to Book Value per Share Ratio

Champions Oncology has a P/B Ratio of 24.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.51% of the float of Champions Oncology has been sold short.

Short Interest Ratio / Days to Cover

Champions Oncology has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Champions Oncology has recently increased by 6.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Champions Oncology does not currently pay a dividend.

Dividend Growth

Champions Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.08

Percentage of Shares Shorted

1.51% of the float of Champions Oncology has been sold short.

Short Interest Ratio / Days to Cover

Champions Oncology has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Champions Oncology has recently increased by 6.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 1.04

News Coverage This Week

MarketBeat has tracked 4 news articles for Champions Oncology this week, compared to 4 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Champions Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

46.98% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CSBR Stock Analysis - Frequently Asked Questions

How were Champions Oncology's earnings last quarter?

Champions Oncology, Inc. (NASDAQ:CSBR) released its quarterly earnings data on Monday, September, 15th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $13.99 million for the quarter. Champions Oncology had a trailing twelve-month return on equity of 87.76% and a net margin of 5.19%.
Read the conference call transcript.

What other stocks do shareholders of Champions Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include Intel (INTC), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Advanced Micro Devices (AMD) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 9/15/2025
• Today: 10/16/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CSBR
• CIK: 771856
• Web: www.championsoncology.com
• Phone: (201) 808-8400
• Fax: 410-369-0390
• Employees: 143
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Champions Oncology: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +80.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: 33.25
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $4.70 million
• Net Margins: 5.19%
• Pretax Margin: 4.99%
• Return on Equity: 87.76%
• Return on Assets: 9.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.93
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: $56.94 million
• Price / Sales: 1.61
• Cash Flow: $0.46 per share
• Price / Cash Flow: 14.41
• Book Value: $0.27 per share
• Price / Book: 24.63

Miscellaneous

• Outstanding Shares: 13,780,000
• Free Float: 7,305,000
• Market Cap: $91.64 million
• Optionable: Optionable
• Beta: 0.55